Evolution of Left Ventricular Hypertrophy After Stabilisation of Chronic Kidney Disease: Results of a Prospective Study

Background: Left ventricular hypertrophy (LVH) is a common and serious cardiovascular complication in patients with chronic kidney disease (CKD), contributing significantly to morbidity and mortality. Whether LVH can regress after stabilisation of CKD remains a key clinical question.
Objective: To evaluate the regression of LVH after one year of optimised treatment aimed at stabilising renal function and controlling cardiovascular risk factors in patients with CKD stages 3 to 5.
Methods: A prospective study included 40 patients (30–75 years old) with CKD stages 3–5 and echocardiographic LVH. Patients received optimised management over 12 months, including tight blood pressure control (<130/80 mmHg), correction of anaemia, and management of phosphocalcium metabolism. Echocardiographic measurements of left ventricular mass index (LVMI) were compared at baseline and after 12 months.
Results: After 12 months, 70% of patients showed regression of LVH, with complete normalisation in 25% and partial reduction in 45%. Regression was associated with optimal blood pressure control (p<0.01), effective correction of anaemia (p<0.05), and treatment of phosphocalcium disorders (p<0.05). Conversely, persistent LVH (30%) was linked to advanced myocardial fibrosis, rapid CKD progression (GFR <15 ml/min), and poor treatment adherence. LVH regression was accompanied by improved diastolic function, reduced NT-proBNP levels, fewer heart failure symptoms, and a 40% decrease in hospitalisations for cardiac decompensation.

Left ,Ventricular ,Hypertrophy, Stabilisation ,Chronic Kidney Disease

1. London GM, Marchais SJ, Guerin AP, et al (2001). Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Journal of the American Society of Nephrology, 12(2), 473-481.
→ Describes the impact of CKD on cardiac structure, including the development of LVH. [Google Scholar] [Crossref]

2. Mizuno M, Shimizu M, Matsumoto Y, et al. (2018). Regression of left ventricular hypertrophy after strict blood pressure control in patients with chronic kidney disease. Hypertension Research, 41(8), 650-658.
→ Confirms that optimised management of hypertension in patients with CKD promotes regression of LVH. [Google Scholar] [Crossref]

3. Wright JT Jr, Bakris G, Greene T, et al (2002). Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA, 288(19), 2421-2431.
→ Highlights the effect of RAAS inhibitors on the regression of LVH. [Google Scholar] [Crossref]

4. Singh AK, Szczech L, Tang KL, et al (2006). Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine, 355(20), 2085-2098.
→ Shows the impact of correction of anemia on LVH and cardiac function. [Google Scholar] [Crossref]

5. Drüeke TB, Locatelli F, Clyne N, et al (2006). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine, 355(20), 2071-2084.
→ Confirms that optimisation of phosphocalcium metabolism and anaemia reduces ventricular remodelling. [Google Scholar] [Crossref]

6. Querejeta R, Varo N, López B, et al. (2004). Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive patients. Circulation, 110(7), 812-817.
→ Demonstrates that myocardial fibrosis limits the reversibility of LVH. [Google Scholar] [Crossref]

7. Briet M, Bozec E, Laurent S, et al. (2012). Arterial stiffness and pulse pressure amplification in chronic kidney disease patients. Hypertension, 60(1), 145-150.
→ Describes the association between CKD progression, arterial stiffness and LVH. [Google Scholar] [Crossref]

8. Dahlof B, Pennert K, Hansson L. (2002). Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies. American Journal of Hypertension, 15(8), 692-700.
→ Shows the impact of LVH regression on cardiovascular mortality and quality of life. [Google Scholar] [Crossref]

9. Heerspink HJ, Perkovic V, Jardine MJ, et al. (2020). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295-2306 [Google Scholar] [Crossref]

• Tribal Child Nutrition and Health in District of Sundargarh: A Public Health Review of ICDS Intervention
• Knowledge, Attitudes and Practices Towards Prostate Cancer Screening Amongst Men Aged 40-60 Years in The Buea Health District: A Cross-Sectional Study
• Compliance with JCI Protocols: A Focus on Employee Safety
• Influence and Involvement of Teachers in Menstrual Hygiene Management of Female Secondary School Students in Kogi State, Nigeria
• A Critical Evaluation of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana in Bihar